Danshen Injection With Ulcerative Colitis Platelet Activation (blood Stasis) And The Experimental Study And Clinical Observation Of The State Intervention Effects

Ulcerative colitis is a cause of chronic nonspecific inflammation of unknown diseases, the main violations of distal colon and rectal mucosa and submucosa may be involved or even the entire colon terminal ileum. The disease to be bloody mucus, abdominal pain, tenesmus as the main symptoms, severity of the poor, and has recurrent trends; UC pathogenesis has not been clear, modern medicine and consider the major environmental factors, immune factors, inflammation, eating disorders, emotional stimulation and genetic and other factors; in the treatment of the application 5 - aminosalicylic acid, corticosteroids, immunosuppressive agents such as drugs, individual differences in greater efficacy. The disease to be bloody mucus, abdominal pain, tenesmus as the main symptoms, severity of the poor, has in recent years, with the continuous development of Chinese medicine formulations, traditional Chinese and western medicine in the treatment of ulcerative colitis on a breakthrough has been made, and has targeted strong, diverse treatment side effects, efficacy and other advantages of the exact.In this paper, the literature review of recent applications huoxuehuayu treatment of ulcerative colitis platelet activation (blood) the state of progress in clinical treatment are summarized, the main introduction of Western medicine and Chinese medicine for the disease of platelet activation (blood) the state of knowledge Clinical (dialectic) sub-type, internal and external use drugs and acupuncture treatment progress, and clinical efficacy analysis, pointing out that the existing problems, and look forward to the prospect of disease study.Methods: Experimental study: The 60 UC patients (all patients are Changchun University of Traditional Chinese Medicine from the first clinical hospital and outpatient hospitalization) were randomly divided into two groups (ie, control group 30, treatment group 30), control group 30 patients with simple oral "enteric-coated tablets of mesalazine (5 - amino salicylic acid)" 0.5g three times a day; Treatment group, 30 patients with the exception of oral "enteric-coated tablets of mesalazine (5 - amino salicylic acid)" 0.5g three times a day, but also static point of compound Danshen injection (16ml add 5% glucose 100ml) Day 1 (above each group are 20 days for one course of treatment, a total of two treatments). Medication in the treatment of pre-and post-treatment, respectively 60 UC patients with mining 5ml blood samples, using enzyme-linked immunosorbent assay detection of platelet granule membrane proteinа-140 (GMP-140), thromboxane B2 (TXB2); Automatic blood cell analyzer Detect mean platelet volume (MPV), platelet (PLT) count, and detailed records and clinical analysis. Clinical Research: Clinical research, Western diagnostic criteria adopted in 2001 in Chengdu meeting diagnostic criteria for UC, the diagnosis of TCM and Western Medicine in the diagnostic criteria on the basis of the reference to the development of People's Republic of China Ministry of Health released "Chinese medicine clinical research guiding principles - China Medical Technology Press .2004 "to carry out the relevant part of Syndromes. The 60 UC patients (all patients are Changchun University of Traditional Chinese Medicine from the first clinical hospital and outpatient hospitalization) were randomly divided into two groups (ie, control group 30, treatment group 30), control group 30 patients with pure oral "and the United States Mesalazine Enteric-coated Tablets (5 - amino salicylic acid) "0.5g three times a day; Treatment group, 30 patients with the exception of oral "enteric-coated tablets of mesalazine (5 - amino salicylic acid)" 0.5g three times a day, but also static point of compound Danshen injection (16ml add 5% glucose 100ml) Day 1 (above each group are 20 days for one course of treatment, a total of two treatments). Separately before and after treatment at the Clinical Record to witness changes in treatment after 6 months of follow-up follow-up efficacy assessment. Clinical observations indicate that the treatment results show that: the treatment group complete remission rate of 46.67%, the total effective rate 86.67%, control group, complete remission rate of 16.67%, the total effective rate 53.30%.During the discussion part of ulcerative colitis pathogenesis, classification and treatment methods are discussed on the Danshen injection on platelet activation in ulcerative colitis (blood) state intervention effects were evaluated.